ClinicalTrials.gg
RecruitingNCT07741448Updated Aug 3, 2026

Neoadjuvant Gemcitabine Plus Trastuzumab Rezetecan in HER2-positive UTUC

A Phase 2 interventional study of Trastuzumab Rezetecan and Gemcitabine in UTUC, sponsored by Zhiquan Hu. Recruiting at 10 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-03.

Sponsored by Zhiquan Hu · Phase 2, Interventional, and Treatment

How we know · 3 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
54
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

Upper tract urothelial carcinoma (UTUC) carries a poor prognosis, with conventional GC (gemcitabine plus cisplatin) regimens achieving only a 19% pathological complete response (pCR) rate in the neoadjuvant setting. Antibody-drug conjugates (ADCs) have shown promising results in advanced urothelial carcinoma, Meanwhile the clinical application of traditional cisplatin-based chemotherapy is associated with significant limitations. Therefore, exploring the efficacy and safety of Trastuzumab Rezetecan (an anti-HER2 ADC) combined with gemcitabine in UTUC is of considerable importance.

This trial will enroll patients with HER2 2-3+ UTUC. After pathological diagnosis, patients will receive intravenous infusions of gemcitabine and Trastuzumab Rezetecan. The treatment regimen consists of a 21-day cycle: 4 cycles of neoadjuvant therapy, followed by 2 cycles of adjuvant therapy for patients who do not achieve pCR (total of 6 cycles). For patients with suboptimal pathological downstaging after surgery (≥ypT3 or ypN+), combination with immune checkpoint inhibitors (ICIs) is recommended.

During the neoadjuvant period, adverse events will be closely monitored. Regular imaging and follow-up assessments will be performed, and events such as disease recurrence, progression, and their corresponding time points will be documented.

The primary endpoint is pCR rate. Secondary endpoints include adverse events during the neoadjuvant period, event-free survival (EFS), overall survival (OS).

02

Conditions studied

  • UTUC

Keywords

  • Trastuzumab Rezetecan
  • Gemcitabine
  • UTUC
  • neoadjuvant therapy
03

In context

Lead sponsor

Zhiquan Hu is the lead sponsor of 2 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The subject voluntarily participates in the study, provides written , and is able to comply with study procedures and follow-up visits.
  2. Aged between 18 and 75 years.
  3. Patients diagnosed with upper tract urothelial carcinoma (UTUC) who are candidates for radical nephroureterectomy with bladder cuff excision.
  4. Clinical stage T1N0M0 - T2-T4aN1M0 (evaluated by CT/MRI/PET-CT).
  5. Histopathology confirms urothelial carcinoma as the predominant component; IHC testing shows expression of 2+ to 3+.
  6. performance status ≤ 2.
  7. Laboratory parameters meet all of the following criteria:

    • ≥ 1.5 × 10⁹/L
    • ≥ 100 × 10⁹/L; ≥ 90 g/L
    • Total ≤ 1.5 ×
    • (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP) ≤ 2.5 × ULN; serum creatinine ≤ 3 × ULN
  8. Cardiac function: (NYHA) classification \< Grade III.

Exclusion criteria

Exclusion Criteria:

  1. Received within 4 weeks prior to enrollment or plan to receive such vaccines during the study.
  2. Received systemic chemotherapy, /PD-L1 agents, or -targeted therapy within the previous 6 months.
  3. Known to gemcitabine, Trastuzumab Rezetecan, or any of their .
  4. Active, known or suspected disease.
  5. Known history of primary immunodeficiency.
  6. Known history of solid organ allotransplantation or hematopoietic stem cell transplantation.
  7. Female patients who are pregnant or breastfeeding.
  8. Untreated acute or chronically active or infection. Patients receiving antiviral therapy may be considered eligible at the investigator's discretion with ongoing viral load monitoring.
  9. Uncontrolled concurrent illnesses, including but not limited to:

    1. infection (positive HIV antibody).
    2. Severe active infection with inadequate clinical control.
    3. Evidence of severe or uncontrolled systemic disease (e.g., severe psychiatric or neurological disorders, epilepsy or dementia; unstable or decompensated respiratory, cardiovascular, hepatic or renal disease; uncontrolled hypertension defined as Grade ≥2 hypertension despite medical treatment).
  10. Active bleeding, newly diagnosed thromboembolic disease requiring therapeutic anticoagulation, or bleeding diathesis.
  11. Diagnosis of another malignant tumor within the past 5 years.
  12. Active tuberculosis
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
54 participants (estimated)

Study arms

  • Experimental
    Trastuzumab Rezetecan plus Gemcitabine Group

    Drug: Trastuzumab Rezetecan · Drug: Gemcitabine · Procedure: Radical nephroureterectomy

Interventions

  • Gemcitabine 1000 mg/m² is given via intravenous infusion, followed by intravenous administration of trastuzumab rezetecan 4.8 mg/kg 3 hours thereafter. The treatment consists of 4 cycles in total with a 21-day cycle interval. Patients without pathological complete response (pCR) will receive 2 cycles of adjuvant therapy

  • Gemcitabine 1000 mg/m² is given via intravenous infusion, followed by intravenous administration of trastuzumab rezetecan 4.8 mg/kg 3 hours thereafter. The treatment consists of 4 cycles in total with a 21-day cycle interval. Patients without pathological complete response will receive 2 cycles of adjuvant therapy

  • ProcedureRadical nephroureterectomy

    After completing four cycles of neoadjuvant therapy, patients undergo radical nephroureterectomy (RNU). The surgical resection typically includes: 1\) The affected kidney (including the perirenal fat capsule); 2) The entire ureter from the renal pelvis to the intramural segment; 3) A bladder cuff around the ureteral orifice; 4) In addition, ipsilateral regional lymph node dissection (e.g., hilar, para-aortic, and paracaval nodes) may be performed depending on tumor stage and clinical indication.

06

What researchers measure

Primary outcomes

  1. Pathological Complete Response (pCR)

    Defined as the absence of residual viable tumor cells (ypT0N0) in RNU specimens. Assessed post surgery. Method: A central pathology review committee performs review of slides from all eligible patients. Two senior uropathologists (associate professor level or above) read independently; consensus is final, otherwise a third senior pathologist adjudicates blindly. ypT and ypN are recorded.

    Time frame: Within 1 week after completion of radical nephroureterectomy

Secondary outcomes

  1. Treatment Related Adverse Events During Neoadjuvant Therapy

    The patients will be evaluated according to CTCAE 5.0 during neoadjuvant therapy. Assessed from the first cycle to 4 weeks after the last cycle, with comprehensive tests each cycle, a scheduled visit 1 week after the last dose of each cycle, and immediate evaluation upon any alert or complaint. Method: Uniform site training, structured eCRF recording of AE terms, dates, grades, relatedness, actions, outcomes. An independent Clinical Endpoint Committee conducts centralized review of all Grade ≥3 events for final adjudication.

    Time frame: The period starting from the first administration of neoadjuvant therapy and extending through 4 weeks following the last dose.

Other outcomes

  1. Event-Free Survival

    Defined as time from neoadjuvant start to first occurrence of: disease progression (local/regional recurrence, distant metastasis, or definite clinical progression); death from any cause; initiation of new anti-cancer therapy due to progression or toxicity. Censored at last known event-free assessment. Assessed at scheduled visits. Method: A central follow-up unit conducts structured symptom queries; any suspected event triggers medical evaluation. All potential event materials (imaging, records, symptom logs, death certificates) are submitted to an independent CEC for adjudication of event and date, final for analysis.

    Time frame: From date of first neoadjuvant dose until the date of first documented events above, whichever came first, assessed up to 36 months

  2. Overall Survival

    Defined as time from neoadjuvant start to death from any cause. Assessed at scheduled visits. Method: Central follow-up unit collects objective death documents from multiple sources. The independent CEC reviews all documents, verifies and adjudicates the exact date of death, which serves as the final basis for OS calculation.

    Time frame: From date of first neoadjuvant dose until the date of death from any cause, assessed up to 36 months.

07

Study locations

10 of 10 sites recruiting
  • Huanggang Central Hospital
    Huanggang, Hubei 438000, China
    Recruiting
    • Jiayi Tao, M.D. · Contact35149051@qq.com · 86+13409868766
    • Jiayi Tao, M.D. · Principal investigator
  • Jingzhou Central Hospital
    Jingzhou, Hubei 434020, China
    Recruiting
    • Yixiang Liao, M.D. · Contact25261193@qq.com · 86+18107167675
    • Yixiang Liao · Principal investigator
  • Taihe Hospital
    Shiyan, Hubei 442000, China
    Recruiting
    • Congbo Chen, M.D. · Contact86+13907204825
    • Congbo Chen, M.D. · Principal investigator
  • The Central Hospital of Wuhan
    Wuhan, Hubei 430014, China
    Recruiting
    • Yonglian Guo, M.D. · Contact15972152299@139.com · 86+15972152299
    • Yonglian Guo, M.D. · Principal investigator
  • Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technolog
    Wuhan, Hubei 430030, China
    Recruiting
    • Zhiquan Hu, M.D. · Contacthuzhiquan2000@163.com · 86+13971656164
    • Chunguang Yang, M.D. · Sub investigator
    • Haijun Huang, M.M. · Sub investigator
    • Zhiquan Hu, M.D. · Principal investigator
  • Renmin Hospital of Wuhan University
    Wuhan, Hubei 430060, China
    Recruiting
    • Zhiyuan Chen, M.D. · Contactchenzhiyuan163@163.com · 86+13886000807
    • Zhiquan Chen, M.D. · Principal investigator
  • Zhongnan Hospital of Wuhan University
    Wuhan, Hubei 430071, China
    Recruiting
    • Xingyuan Xiao, M.D. · Contactxiaoxingyuan@whu.edu.cn · 86+18672923313
    • Xingyuan Xiao, M.D. · Principal investigator
  • Hubei Cancer Hospital
    Wuhan, Hubei 430079, China
    Recruiting
    • Youyuan Li, M.D. · Contact86+18871188109
    • Youyuan Li, M.D. · Principal investigator
  • Xiangyang Central Hospital
    Xiangyang, Hubei 441021, China
    Recruiting
    • Bin chen, M.D. · Contact625848080@qq.com · 86+19908671399
    • Bin Chen, M.D. · Principal investigator
  • Yichang Central People's Hospital
    Yichang, Hubei 443003, China
    Recruiting
    • Xiaobo Chen, M.D. · Contact272899447@qq.com · 86+13972587419
    • Xiaobo Chen, M.D. · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Aug 2026; primary completion for Aug 2028, 24 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 29, 2026
First posted
Aug 3, 2026
StartEst.
Aug 15, 2026
Primary completionEst.
Aug 15, 2028
CompletionEst.
Aug 15, 2029
Last update
Aug 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07741448
Lead sponsor
Zhiquan Hu
Responsible party
Zhiquan Hu (Clinical professor, Tongji Hospital) — Sponsor-investigator
First posted
Aug 3, 2026
Start date
Aug 15, 2026 (estimated)
Primary completion
Aug 15, 2028 (estimated)
Completion
Aug 15, 2029 (estimated)
Last update
Aug 3, 2026

Study contacts

Zhiquan Hu, M.D.
Contact
huzhiquan2000@163.com
86+13971656164
Chunguang Yang, M.D.
Contact
cgyang-hust@hotmail.com
86+13871084024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trastuzumab rezetecan

Start the discussion